Business Context and Reporting Period
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing peptide-based candidates for hematology, blood disorders, inflammatory diseases and immunomodulatory diseases. Key programs include rusfertide, PN-943 and PN-235. This unaudited Form 10-Q covers the three and six months ended June 30, 2022, filed August 4, 2022.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2022 | Six Months Ended June 30, 2022 |
|---|---|---|
| License and collaboration revenue | $0.9 million | $26.6 million |
| Research and development expense | $34.6 million | $70.9 million |
| General and administrative expense | $7.7 million | $18.2 million |
| Loss from operations | $41.4 million | $62.6 million |
| Net loss | $41.0 million | $62.0 million |
| Net loss per share | $0.84 | $1.27 |
| Net cash used in operating activities | Not provided for the quarter | $51.3 million |
Revenue was generated from the Janssen collaboration rather than product sales. The company has no approved products, no historical product revenue and has incurred losses since inception. Six-month operating and net loss margins were approximately negative 235% and negative 233%, respectively, based on reported collaboration revenue.
- Cash and cash equivalents at June 30, 2022 were $120.2 million; current marketable securities were $171.7 million.
- Total cash, cash equivalents and marketable securities were $291.9 million, compared with $326.9 million at December 31, 2021.
- Total assets were $310.5 million and stockholders’ equity was $268.0 million.
- No material debt was disclosed. Liabilities primarily consisted of accounts payable, accrued expenses and operating lease liabilities totaling $42.5 million.
- Stock-based compensation expense was $12.7 million for the first six months, compared with $6.6 million in the prior-year period.
Material Changes Versus the Prior Comparable Period
- Second-quarter revenue decreased 62% to $0.9 million from $2.3 million, as services under the Janssen agreement declined and the related performance obligation was completed on June 30, 2022.
- Six-month revenue increased 214% to $26.6 million from $8.5 million, primarily because of a $25.0 million Janssen milestone received in April 2022 for dosing the third patient in the PN-235 FRONTIER 1 Phase 2b trial.
- Second-quarter research and development expense increased 31% to $34.6 million; six-month expense increased 40% to $70.9 million. The increases were driven principally by PN-943 IDEAL trial and manufacturing costs and rusfertide VERIFY Phase 3 costs.
- General and administrative expense increased 15% in the quarter and 44% year to date, reflecting higher personnel, stock-based compensation and business-support costs.
- Six-month net loss increased 13% to $62.0 million from $54.8 million, despite the higher collaboration revenue.
- Operating cash usage was $51.3 million, modestly lower than $52.5 million in the prior-year period. Financing cash inflows declined to $17.6 million from $126.4 million, primarily because the prior-year period included a large public offering.
- In January 2022, the company issued 422,367 shares under its at-the-market facility for net proceeds of $14.6 million. Shares outstanding increased to 48.7 million at June 30, 2022 from 47.8 million at December 31, 2021.
Guidance, Outlook, Commentary and Risks
- Management believes existing cash, cash equivalents and marketable securities will fund anticipated operating and capital requirements for at least 12 months from the filing date.
- Management expects cash burn to approximate current levels for the remainder of 2022 but to decline in 2023. The company expects to require substantial additional financing to advance clinical development and potential commercialization.
- VERIFY, a global Phase 3 rusfertide trial in polycythemia vera, began screening in the first quarter of 2022. Management targeted completion of enrollment by the end of the first half of 2023, while noting slower-than-expected initial enrollment.
- PN-943’s IDEAL Phase 2 trial achieved encouraging results in the 150 mg twice-daily arm, but the 450 mg twice-daily arm did not meet its prespecified primary endpoint. The company was finalizing a potential Phase 3 design and seeking a large pharmaceutical partner.
- The FDA removed the rusfertide clinical hold in October 2021 after the company submitted additional safety information and protocol safeguards. In June 2022, the company voluntarily withdrew rusfertide’s Breakthrough Therapy Designation; its Fast Track designation remained active.
- Janssen discontinued further development of PTG-200 and PN-232 in favor of PN-235. The company remained eligible for approximately $855.0 million of future development and sales milestones, in addition to $112.5 million received to date, plus potential royalties.
- Key risks include clinical failure or delays, patient recruitment challenges, regulatory actions, safety findings, reliance on Janssen and other third parties, manufacturing and supply-chain constraints, COVID-19 impacts, the Russia-Ukraine conflict, inflation, capital-market disruption and the need for additional financing.
- The company had a $1.5 million payment obligation to Zealand due in August 2022 and could owe up to $2.75 million in additional future rusfertide development milestones.
- On July 1, 2022, after quarter-end, exchange warrants for 400,000 shares were net exercised, resulting in the issuance of 399,997 shares.
- Disclosure controls and procedures were reported effective at the reasonable assurance level, with no material changes to internal control over financial reporting during the quarter.
Investor Verification Checklist
- Verify the sustainability of collaboration revenue after completion of the Janssen performance obligation and the timing and probability of future milestones.
- Assess rusfertide safety and regulatory developments following the prior clinical hold, the carcinogenicity finding and withdrawal of Breakthrough Therapy Designation.
- Monitor VERIFY enrollment, trial execution, clinical outcomes and the company’s ability to meet its stated enrollment objective.
- Evaluate PN-943’s Phase 3 strategy, partnering efforts and the implications of the mixed IDEAL Phase 2 results.
- Reconcile cash burn, investment balances and the stated 12-month liquidity outlook against expected clinical-development spending.
- Determine the timing, amount and terms of required future financing, including potential equity dilution or debt restrictions.
- Track Janssen’s continued development of PN-235 and any termination, delay or change in collaboration strategy.
- Review Zealand payment obligations, other contingencies and the dilution impact of outstanding options, warrants, restricted stock units and the post-quarter-end warrant exercise.